Anterogen.Co.,Ltd. announced that it expects to receive KRW 4.9999992 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm
October 24, 2019
Share
Anterogen.Co.,Ltd. (KOSDAQ:A065660) announced a private placement of 105,042 common shares at a price of KRW 47,600 per share for gross proceeds of KRW 4,999,999,200 on October 25, 2019. The transaction will include participation from existing investors Samsung Securities Co. Ltd., Investment Arm for 17,500 common shares, Korea Investment & Securities Co., Ltd., Investment Arm for 32,334 common shares, NH Investment & Securities Co., Ltd., Investment Arm for 7,584 common shares, Mirae Asset Daewoo Co., Ltd., Investment Arm for 5,607 common shares, KB Securities Co., Ltd., Investment Arm for 10,505 common shares, Royal Standard Corporation for 10,504 common shares, and Bum Jin Choi for 21,008 common shares. The shares issued are subject to a restriction period of one year. The transaction has been approved by board of directors of the company. The transaction is expected to close on November 7, 2019.
ANTEROGEN CO.,LTD. is a Korea-based company mainly engaged in the manufacture of cell therapy products. The Company's product portfolio consists of Cupistem which is used for the treatment of Crohnâs fistula by using autologous adipose-derived mesenchymal stem cells; stem cell conditioned medias (SCMs), SCM2s, and Therastem-dermas which are used for strengthening the function of skin as cosmetic raw materials; Remodullins which are used for the treatment of pulmonary arterial hypertension (PAH) and other products which are used for testing services. The Company distributes its products within domestic market.
ANTEROGEN.CO.,LTD. 